POSITION
Co-Investor
BOARD
None
EXIT
IPO (Nasdaq) in June 2020
Vaxcyte, Inc. (Vaxcyte) formerly SutroVax, Inc. is a biopharmaceutical company developing vaccines for infectious disease targets with an initial emphasis on best-in-class conjugate vaccines and protein-based vaccines. Vaxcyte is an independent company that was spun out of Sutro Biopharma with an exclusive license to Sutro Biopharma’s Xpress CF™ platforms for cell free protein synthesis and site-specific conjugation. In addition to CTI Life Sciences Fund II, Vaxcyte is backed by leading investors including Abingworth, Longitude Capital, and Roche Venture Fund.
The company did an IPO (Nasdaq) in June 2020.